Envestnet Asset Management
AKTX

Envestnet Asset Management’s Akari Therapeutics AKTX Stock Holding History

Envestnet Asset Management’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-17
Closed -$29K – 3098
2020
Q2 		$29K Buy
17
+2
+13% +$3.05K ﹤0.01% 3041
2020
Q1 		$17K Buy
15
+2
+15% +$2.79K ﹤0.01% 2942
2019
Q4 		$18K Buy
+13
New +$19.2K ﹤0.01% 3059

Other funds holding AKTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
UAS
United Asset Strategies Garden City, New York $1.41B AUM 27.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Envestnet Asset Management's AKTX Position: Q3 2020 in Review

Envestnet Asset Management sold out of Akari Therapeutics (AKTX) in Q3 2020, closing a stake of 17 shares — an estimated $29K sold.

Envestnet Asset Management first reported a position in AKTX in Q4 2019 and held it in 3 quarters. The position peaked at $29K in Q2 2020. 12 funds tracked by Wall St. Rank hold AKTX as of Q3 2020.

  • Envestnet Asset Management reported no remaining Akari Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Envestnet Asset Management sold 17 Akari Therapeutics shares in Q3 2020, an estimated $29K.
  • Envestnet Asset Management first reported a position in Akari Therapeutics in Q4 2019 and held it in 3 quarters.
  • Envestnet Asset Management's Akari Therapeutics position peaked at $29K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Akari Therapeutics as of Q3 2020.

Based on Envestnet Asset Management's 13F filing for Q3 2020, filed 9 Oct 2020.